Samumed worth $12 billion is working on tissue regeneration to combat alzheimers and more

Samumed has raised $438 million with a $12 billion valuation. Samumed is a leader in medical research and development for tissue-level regeneration. They have a biotechnology platform based on small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.

One of the primary signaling pathways that regulate the self-renewal and differentiation of adult stem cells is the Wnt pathway, which plays a crucial role in tissue health, ranging from formation to replenishment and from repair to regeneration of various tissues.

Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.


Don’t miss the latest future news

Subscribe and get a FREE Ebook